Table 2 Comparison of overall correct responses in knowledge regarding FH between male and female Saudi medical interns. (10 questions, total score 17)
No | Areas of KAP regarding FH being tested | Total (n = 170) | Male (n = 83) | Female (n = 87) | P value |
|---|---|---|---|---|---|
Knowledge items | |||||
3 | Correctly defined FH | 130 (76.50%) | 55 (66.30%) | 75 (86.20%) | 0.002 |
4 | Correctly defined lipid profile of FH | 89 (52.40%) | 27 (32.50%) | 62 (71.30%) | 0.0001 |
6 | Correctly identified FH prevalence | 21 (12.40%) | 12 (14.50%) | 9 (10.30%) | 0.281 |
7 | Correctly identified FH inheritance | 74 (43.50%) | 23 (27.70%) | 51 (58.60%) | 0.0001 |
8 | Correctly identified CAD risk in FH | 12 (7.10%) | 5 (6.00%) | 7 (8.00%) | 0.416 |
11 | Correctly identified that genetic test is not required for accurate FH diagnosis | 78 (45.90%) | 33 (39.80%) | 45 (51.70%) | 0.079 |
22 | Correctly identified target LDL-c level in FH | 8 (4.70%) | 5 (6.00%) | 3 (3.40%) | 0.334 |
23 | Correctly selected family history of premature CAD to be taken in FH | ||||
Consanguinity | 49 (28.80%) | 27 (32.50%) | 22 (25.30%) | 0.191 | |
Family history of premature CHD (age of onset) | 106 (62.40%) | 38 (45.80%) | 68 (78.20%) | 0.0001 | |
Family history of hypercholesterolaemia (TC and/ or LDL-c) | 89 (52.40%) | 37 (44.60%) | 52 (59.80%) | 0.034 | |
Family history of tendon xanthomata | 76 (44.70%) | 26 (31.30%) | 50 (57.50%) | 0.0001 | |
Family history of childhood unexplained death | 73 (42.90%) | 17 (20.50%) | 56 (64.40%) | 0.0001 | |
Three-generation pedigree chart | 19 (11.20%) | 11 (13.30%) | 8 (9.20%) | 0.276 | |
24 | Correctly responded that none of the features given would lead to exclusion of FH diagnosis | 170 (100.00%) | 83 (100.00%) | 87 (100.00%) | – |
25 | Correctly identified that combined statin with ezetimibe is recommended for adult HeFH | ||||
Ezetimibe co-administered with statin therapy is recommended as an option for adult heterozygous FH | 64 (37.60%) | 26 (31.30%) | 38 (43.70%) | 0.066 | |
Lipid lowering drug therapy is considered by the age of 10 years | 17 (10.00%) | 9 (10.80%) | 8 (9.20%) | 0.459 | |
Progress of cascade screening in FH patients should be recorded | 13 (7.60%) | 5 (6.00%) | 8 (9.20%) | 0.314 | |
Overall knowledge of FH (Total Score 17) | 6.40 ± 3.01 (1.00–12.00) | 5.29 ± 2.63 (1.00–12.00) | 7.46 ± 2.98 (1.00–12.00) | 0.0001 | |
Acceptable knowledge (≥ 9.5) | 35 (20.60%) | 6 (7.20%) | 29 (33.30%) | 0.0001 | |
Poor knowledge (< 9.5) | 135 (79.40%) | 77 (92.80%) | 58 (66.70%) | 0.102 | |